Fibromyalgia is not currently classified as an autoimmune disease. The American College of Rheumatology states plainly that fibromyalgia is neither an inflammatory nor an autoimmune condition. Instead, it is understood primarily as a disorder of the nervous system, where the brain and spinal cord amplify pain signals. That said, recent research has uncovered intriguing autoimmune-like features that are challenging the traditional view and could eventually reshape how the condition is understood.
Why Fibromyalgia Isn’t Classified as Autoimmune
Classic autoimmune diseases like rheumatoid arthritis and lupus share a defining pattern: the immune system attacks the body’s own tissues, causing measurable inflammation and, over time, visible damage to joints, organs, or other structures. Blood tests typically reveal elevated inflammatory markers and specific antibodies, and imaging can show the destruction happening inside the body.
Fibromyalgia doesn’t follow this pattern. Standard blood work for inflammation comes back normal or near-normal. X-rays and other imaging show no joint erosion or tissue damage. And unlike autoimmune conditions that progressively destroy the body’s structures, fibromyalgia does not cause lasting damage to joints, muscles, or organs, no matter how long a person has it. One study did find slightly higher levels of a sensitive inflammation marker (high-sensitivity CRP) in fibromyalgia patients compared to healthy controls, with averages of 2.71 versus 1.75. But this modest difference largely disappeared after accounting for factors like body weight and age, suggesting it isn’t a core feature of the disease.
What’s Actually Happening in the Nervous System
The leading explanation for fibromyalgia centers on a process called central sensitization: the brain and spinal cord become overly reactive to pain signals, essentially turning up the volume on sensations that wouldn’t normally be painful. Brain imaging studies consistently show that people with fibromyalgia have greater activation in pain-processing areas compared to people without the condition. There’s also increased connectivity between pain regions and the brain’s default resting network, meaning the brain stays in a heightened alert state even when no painful stimulus is present.
At the same time, the system that normally dials pain signals back down appears to be weakened. The spinal fluid of people with fibromyalgia contains higher-than-normal levels of excitatory chemical messengers, including substance P and glutamate, which ramp up pain signaling. Meanwhile, calming brain chemicals like serotonin and norepinephrine may be out of balance. The result is a nervous system stuck in overdrive: pain signals get amplified on the way up and aren’t properly dampened on the way back down.
This type of pain has a formal name in medicine: nociplastic pain. It means pain arising from changes in how the nervous system processes signals, without any clear tissue damage or nerve injury causing it. It’s a fundamentally different mechanism from autoimmune-driven pain, where inflamed or damaged tissue sends legitimate distress signals to the brain.
Neuroinflammation Adds a Layer of Complexity
While fibromyalgia doesn’t produce the kind of bodywide inflammation seen in autoimmune diseases, there is evidence of inflammation happening inside the brain itself. A PET imaging study found that people with fibromyalgia showed widespread elevations of a marker associated with activated immune cells in the brain called microglia, particularly in the frontal and parietal lobes. This was the first direct, in-vivo evidence of brain immune cell activation in fibromyalgia.
Spinal fluid from fibromyalgia patients also contains elevated levels of chemical signals involved in communication between nerve cells and these brain immune cells. In exploratory findings, higher levels of this brain immune activity correlated with worse fatigue. This neuroinflammation could be a key driver of central sensitization, but it’s a localized process within the nervous system, not the systemic, tissue-destroying inflammation that defines autoimmune disease.
The Autoimmune Evidence That’s Changing the Conversation
Despite the official classification, a line of research published in recent years has introduced a genuinely surprising possibility. Researchers took IgG antibodies (the most common type of immune antibody) from the blood of fibromyalgia patients and injected them into mice. The mice developed heightened sensitivity to pressure and cold, mimicking key fibromyalgia symptoms. When the antibodies were eventually cleared from the mice’s systems, the symptoms resolved completely, and the timeline of recovery matched the known rate at which the body eliminates these antibodies.
This is a significant finding because it suggests that something in the blood of fibromyalgia patients, specifically their antibodies, can directly transfer pain sensitivity to another organism. If confirmed by further work, it would point to an autoimmune mechanism, but one that looks quite different from traditional autoimmune diseases. The antibodies don’t appear to trigger the kind of systemic inflammation or local tissue destruction seen in conditions like rheumatoid arthritis. Instead, they may act directly on the nervous system, potentially explaining why standard inflammatory markers stay relatively normal.
As one commentary in Nature Reviews Rheumatology noted, if an autoimmune basis is confirmed, it would represent “a profound shift in the understanding of the disease” and could open the door to entirely new treatments.
Small Fiber Nerve Damage in Some Patients
Another piece of the puzzle involves the tiny nerve fibers in the skin. Studies have found that roughly 70% of fibromyalgia patients show signs of small fiber nerve damage, such as reduced nerve fiber density in skin biopsies or abnormal responses to temperature testing. This overlaps significantly with a separate condition called small fiber neuropathy, which can have autoimmune causes.
Interestingly, the pattern of nerve fiber loss in fibromyalgia differs from typical nerve damage. Neuropathies usually affect the feet and hands first and spread inward. But in fibromyalgia, researchers found that nerve fiber loss closer to the trunk of the body was twice as common (31%) as in patients with standard small fiber neuropathy (15%). This unusual pattern has led some researchers to speculate that something may be affecting the nerve cell bodies in the spinal area rather than the nerve endings themselves, a pattern also seen in certain autoimmune conditions like Sjögren syndrome.
Why Autoimmune Treatments Don’t Work (Yet)
If fibromyalgia had a straightforward autoimmune mechanism, you’d expect standard immune-suppressing medications to help. They don’t. Anti-inflammatory drugs like ibuprofen and corticosteroids like prednisone have no meaningful effect on fibromyalgia symptoms. Biologic drugs that target specific inflammatory molecules, the kind that have transformed treatment for rheumatoid arthritis and other autoimmune conditions, have not been studied rigorously in fibromyalgia, and the limited data available doesn’t support their use.
This treatment resistance is one of the strongest practical arguments against classifying fibromyalgia as autoimmune. The medications that work best for fibromyalgia target the nervous system: drugs that increase serotonin and norepinephrine, medications that calm overactive nerve signaling, and approaches like exercise and cognitive behavioral therapy that can help retrain the brain’s pain processing. If the antibody research pans out, though, treatments that filter or neutralize specific antibodies could eventually become relevant.
The Overlap With Autoimmune Conditions
Fibromyalgia shows up alongside confirmed autoimmune diseases at striking rates. Between 20% and 30% of people with rheumatoid arthritis also meet the criteria for fibromyalgia. Data from one large database found that people with fibromyalgia were 2 to 6 times more likely to also have rheumatoid arthritis or lupus compared to people without fibromyalgia.
This overlap has traditionally been explained by the idea that chronic pain from an autoimmune condition can eventually rewire the nervous system into a sensitized state, essentially triggering fibromyalgia as a secondary problem. But the antibody research raises an alternative possibility: some of these patients may have developed a separate autoimmune reaction that produces fibromyalgia independently. For now, the distinction matters because fibromyalgia symptoms don’t improve when the underlying autoimmune condition is treated with immunosuppressants, meaning it needs to be addressed on its own terms regardless of what’s happening alongside it.
Where Things Stand
Fibromyalgia sits in a genuinely uncertain place in medicine. The official classification is clear: it is a disorder of central pain processing, not an autoimmune disease. Standard diagnostic workups show no systemic inflammation, no tissue damage, and no response to immune-suppressing treatment. But emerging evidence of symptom-transferring antibodies, brain immune cell activation, and patterns of nerve damage that mirror autoimmune conditions suggests the picture is more complicated than the current label implies. For people living with fibromyalgia today, the practical reality is that treatments targeting the nervous system remain the most effective approach, while the autoimmune question continues to be investigated.